APD811-301 Phase 3 studies evaluating the efficacy and safety of ralinepag in patients with WHO Group 1 pulmonary arterial hypertension (PAH)

Brief description of study

The purpose of this research study is to assess an investigational medication called ralinepag (also referred to as the “investigational study drug”) in the treatment of pulmonary arterial hypertension (PAH). Ralinepag has not been approved by any regulatory authorities, including the US Food and Drug Administration (FDA); therefore, it is not available by prescription.

Clinical Study Identifier: s18-00438
ClinicalTrials.gov Identifier: NCT03626688

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.